iRhythm Holdings (LTS:0A7L) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0A7L iRhythm Holdings Inc LTS:0A7L
69 GF Score
Price $115.18
GF Value $162.69
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is iRhythm Holdings FFO?

FFO (Funds from operations) only applies to REITs.

LTS:0A7L
69GF Score
iRhythm Holdings Inc LTS:0A7L
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is iRhythm Holdings (LTS:0A7L) Overvalued in 2026?

Based on GuruFocus' analysis, iRhythm Holdings stock appears to be undervalued. The current stock price of $115.18 is trading 29.2% below its estimated GF Value™ of $162.69. GuruFocus considers iRhythm Holdings to be Modestly Undervalued.

Key valuation signals for LTS:0A7L:

  • FFO:
  • GF Value™: $162.69 vs. price of $115.18 (29.2% below fair value)
  • GF Score™: 69/100 with 1 warning sign

No single metric tells the full story. See the LTS:0A7L stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


iRhythm Holdings Business Description

Other Exchanges IRTC:USA
Address 699 8th Street, Suite 600, San Francisco, CA, USA, 94103
iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.
69GF Score

Get the complete analysis for LTS:0A7L

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$115.18
Price
$162.69
GF Value